Alameda, Calif.– Alveo Technologies, a biotech firm specializing in molecular diagnostics, has announced the appointment of Nobel Prize-winning scientist Dr. James Rothman to its Board of Directors. Rothman, a distinguished biochemist and cell biologist, brings decades of scientific and industry experience to the company as it advances its IntelliSense™ molecular detection platform.
Dr. Rothman was awarded the Nobel Prize in Physiology or Medicine in 2013 for his groundbreaking discoveries in the field of cellular transport, specifically the mechanisms that regulate vesicle traffic within cells—a fundamental process also involved in how viruses infect cells. His research has significantly advanced the understanding of cell biology and virology.
“With its technology, Alveo is shifting the paradigm in rapid molecular testing for infectious disease in animals,” Rothman said. “Animal health is deeply connected to human health and our shared environment. I’m honored to support Alveo’s mission and contribute to the development of tools that improve disease surveillance and outbreak management.”
Alveo Technologies is known for its work in point-of-need diagnostics aimed at enabling rapid detection of pathogens. The company’s CEO, Shaun Holt, welcomed Rothman’s appointment, emphasizing the importance of his scientific expertise and deep understanding of academic and industrial research.
“Dr. Rothman is a world-renowned scientist whose insights will be invaluable as we scale our diagnostic capabilities,” said Holt. “His experience will help us forge strategic partnerships and continue innovating in both academic and commercial spheres.”
Rothman is currently the Sterling Professor of Cell Biology at Yale University and the founder of the university’s Nanobiology Institute. He has held positions at leading institutions including Stanford University, Columbia University, and Memorial Sloan-Kettering Cancer Center. In addition to his academic achievements, he has held leadership and advisory roles in the healthcare industry, including with GE Healthcare, Johnson & Johnson, GlaxoSmithKline, and Eli Lilly.
Rothman holds a Ph.D. in Biological Chemistry from Harvard University and a bachelor’s degree in physics from Yale. Over the course of his career, he has earned numerous prestigious awards, including the Lasker Basic Science Award and the Kavli Prize in Neuroscience.
His addition to Alveo’s board marks a significant step in the company’s efforts to expand the reach and impact of its diagnostic technology, particularly in addressing the global health challenges posed by infectious diseases.
